Compare Inovio Pharmaceuticals Inc (INO) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Teradyne, Inc. — how do they compare? Inovio Pharmaceuticals Inc trades at $1.1 (market cap $112.19M), while Teradyne, Inc. trades at $405.84 (market cap $62.34B). The key difference: Teradyne, Inc. is far larger — about 555.7× Inovio Pharmaceuticals Inc's market cap, and Teradyne, Inc. pays a 0.13% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Teradyne, Inc. for 37 Days on average.
| INO | TER | |
|---|---|---|
Market Cap | $112.19M | $62.34B |
Volume | 3,201,278 | 3,368,404 |
Sector | Health | Technology |
52-Week High | $2.65 | $483.84 |
52-Week Low | $0.66 | $132.05 |
Typical Hold Time | 43 Days | 37 Days |
Enterprise Value | $83.51M | $62.08B |
Dividend Yield | — | 0.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $1.155, up 2.21% today, while showing bearish technical signals with negative cash flow and substantial losses. The company's financials reveal minimal revenue of $65,340 against an $84.95 million net loss in 2025, with profitability metrics deeply negative. However, analyst sentiment is optimistic with a 58.83% buy rating and $2.75 consensus price target, driven by the upcoming FDA decision on INO-3107 for recurrent respiratory papillomatosis by October 30, 2026.
INO presents high-risk speculation with potential for significant upside if FDA approval is secured, but carries substantial fundamental weaknesses including persistent cash burn and negative margins. Investors should weigh the binary outcome of the regulatory decision against the company's challenging financial position and technical bearishness.
Teradyne (TER) trades at $411.78, down 4.31% today but maintains strong technical momentum with bullish moving averages and support at $407. The company demonstrates robust fundamentals with 59.24% gross margins and consistent earnings beats, including Q2 2026 EPS of $2.47 versus $2.09 expected. Recent product launches like Magnum E2 and Iris 100 position TER to capitalize on AI-driven semiconductor testing demand.
TER offers compelling growth potential with 61% analyst buy ratings and a $461.50 price target representing 12% upside. However, elevated valuations (P/E 56.56) and cyclical semiconductor exposure present risks. The stock's outlook remains positive driven by AI infrastructure spending and expanding test portfolio, though investors should monitor competitive pressures and industry demand cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
